CCL2 and breast carcinoma: More importantly, a recent study indicated that directly targeting CCL2 may provoke unexpected adverse effects, indicating that cessation of CCL2 inhibition leads to a rebound in the number of circulating monocytes, increasing angiogenesis, promoting metastases, and accelerating death in the breast cancer model [15].